By La Provence (with AFP)
The protection conferred by Moderna’s Covid-19 vaccine remains strong for at least six months and the booster doses currently being tested against the variants are showing results “robust “the US biotech company said Thursday.
According to clinical trials conducted on thousands of people, the vaccine’s effectiveness is 93% six months after the injection of the second dose, Moderna said in a statement released on the occasion of its second quarter results. “We are satisfied that our Covid-19 vaccine shows lasting efficacy of 93% over six months, but we recognize that the Delta variant is a significant new threat, so we must remain vigilant.”, said the boss of Moderna, Stéphane Bancel, quoted in the press release.
The company is testing several versions of a booster dose to increase immune protection against variants: a third dose of the initial vaccine, a new formula based on the Beta variant (first identified in South Africa), and a dose containing in equal parts the initial vaccine and the new formula. The three different candidates “triggered robust antibody production” against the Delta variant, as well as against the Gamma and Beta variants, Moderna said.
The results of these phase 2 trials have been submitted for publication in a scientific journal, she said. The company, which has applied for full authorization for its vaccine in the United States, also said it expected to have provided in August all the information necessary to obtain it.